226 related articles for article (PubMed ID: 38132167)
1. Modeling RET-Rearranged Non-Small Cell Lung Cancer (NSCLC): Generation of Lung Progenitor Cells (LPCs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs).
Marcoux P; Hwang JW; Desterke C; Imeri J; Bennaceur-Griscelli A; Turhan AG
Cells; 2023 Dec; 12(24):. PubMed ID: 38132167
[TBL] [Abstract][Full Text] [Related]
2. Impact of the overexpression of the tyrosine kinase receptor RET in the hematopoietic potential of induced pluripotent stem cells (iPSCs).
Marcoux P; Imeri J; Desterke C; Latsis T; Chaker D; Hugues P; Griscelli AB; Turhan AG
Cytotherapy; 2024 Jan; 26(1):63-72. PubMed ID: 37921725
[TBL] [Abstract][Full Text] [Related]
3. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
4. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
5. Transcriptional landscape of a RET
Hadoux J; Desterke C; Féraud O; Guibert M; De Rose RF; Opolon P; Divers D; Gobbo E; Griscelli F; Schlumberger M; Bennaceur-Griscelli A; Turhan AG
Stem Cell Res; 2018 Jan; 26():8-16. PubMed ID: 29197744
[TBL] [Abstract][Full Text] [Related]
6. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
[TBL] [Abstract][Full Text] [Related]
7. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract][Full Text] [Related]
9. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
[TBL] [Abstract][Full Text] [Related]
10. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
[TBL] [Abstract][Full Text] [Related]
11. Pralsetinib for the treatment of non-small cell lung cancer.
Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
[TBL] [Abstract][Full Text] [Related]
12. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
13. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
16. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
Zhao L; Zhang J; Wang N; Zhang D; Wang Z; Yu Y; Mei Q; Liao D; Jia Y; Kong F
Anticancer Drugs; 2023 Oct; 34(9):979-984. PubMed ID: 36729098
[TBL] [Abstract][Full Text] [Related]
18. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
19. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]